News | August 13, 2025
Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
With this addition, the company’s total Installed MCC Capacity will rise to 30,000 MTPA
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
_256_384.jpg)
iCaltech is engaged in the design, development, and commercialisation of diagnostic medical equipment and apparatus
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Acquisition to be followed by merger; strengthens Torrent’s IPM market presence
Changhua site meets international regulatory standards for global medical applications
The Swiss peptide and oligonucleotide manufacturers roll out major investments across site networks in US, UK and Switzerland
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
The 16,000-square-foot expansion enhances DuPont’s global sterile operations
Subscribe To Our Newsletter & Stay Updated
